Gustave Roussy at ESMO Congress 2024

Bringing together more than 31,000 international experts, the European Society of Medical Oncology (ESMO) annual congress is one of the highlights of global oncology. This year, it will be held from 13 to 17 September in Barcelona. Gustave Roussy, the leading cancer research and treatment centre in France and Europe, ranked fourth globally, is one of the key players at this year's event.

Doctors, researchers, industrialists and patient representatives committed to combating cancer are all meeting in Barcelona this year for the 2024 edition of ESMO.

Gustave Roussy’s presentations

During a presidential session, which brings together “presentations of cutting-edge studies and significant clinical studies that change clinical practice”:

• Dr. Sofia Rivera presents the results of the phase III HypoG-01 study sponsored by Unicancer, which focuses on breast cancer at the locoregional stage: is hypofractionated radiotherapy over a 3-week period as effective as the standard 5-week regimen? The results of this study, under embargo up to the date of presentation, could in the future change the management of all women treated for breast cancer in France and worldwide. Sunday 15 September.
  ► Read the press release
  ► Watch the video online
  

During proffered paper sessions :

• Dr. Jordi Remon presents the results of the phase II PECATI study in patients with thymus gland cancer. It concerns patients with type B3 thymoma or advanced pretreated thymic carcinoma. These studies evaluate the efficacy and safety of lenvatinib, a targeted therapy, in combination with pembrolizumab. Friday 13 September.
  ► Read the press release
  ► Watch the video online
• Dr. Barbara Pistilli presents the first results of the phase II ICARUS-BREAST01 study, sponsored by Gustave Roussy. This study looks at the efficacy, safety, and analysis of biomarkers of a drug-antibody conjugate, patritumab-deruxtecan (HER3-DXd), in patients with advanced HR+/HER2- breast cancer. Friday 13 September.
  ► Read the press release
  ► Watch the video online
• Prof. Benjamin Besse examined the mechanisms of resistance developed by patients with EGFR-mutant advanced non-small cell lung cancer when amivantamab is used in combination with lazertinib as first-line treatment, compared with osimertinib alone. This work is an analysis of the MARIPOSA phase III trial. Saturday 14 September.
  ► Read the press release
  ► Watch the video online
• Dr. Benjamin Verret presents the results of MULTISARC, the first randomised precision medicine study focusing on soft tissue sarcomas, a heterogeneous group of rare tumours that includes more than 70 histological subgroups. The objective is to evaluate the feasibility of high-throughput sequencing in these patients and measure the contribution of molecular profiling. Monday 16 September.
  ► Read the press release
  ► Watch the video online

In addition, three Gustave Roussy physicians are co-authors of studies presented during a presidential session:

• Dr. Yohann Loriot is co-author of the EORTC-GUCG 1333/PEACE-3 study, which compares enzalutamide versus a combination of radium-223 and enzalutamide in patients with hormone-refractory prostate cancer that has metastasised to the bones. The results will be commented on and put into perspective by Prof. Karim Fizazi as an invited discussant.  Saturday 14 September.
• Prof. Fabrice Barlesi, General Director of Gustave Roussy, is the last author of the PIONeeR study, which looks at the mechanisms of resistance to PDL1 inhibitors developed in certain patients with non-small cell lung cancer. Monday 16 September.
• Dr. Sophie Postel-Vinay is co-author of a phase I study focusing on AMG 193, a PRMT5 inhibitor prescribed to patients with metastatic or locally advanced solid tumours with MTAP gene deletion. Monday 16 September.

Finally, Gustave Roussy’s physicians actively participate in this edition of ESMO as co-chairs of proffered paper sessions and/or commenting on study results:

• Prof. Fabrice André co-chairs the third presidential session "Eyes to the future". Monday 16 September.
• Prof. Benjamin Besse co-chairs the proffered paper session on non-small cell metastatic lung cancer. Saturday 14 September.
• Dr. Maria Alice Franzoi discusses the results of two studies focusing on breastfeeding in women with breast cancer in a session on palliative and supportive care. Saturday 14 September.
• Prof. Michel Ducreux co-chairs the proffered paper session on gastrointestinal tumours, and will be putting the results of two studies presented at this session into perspective. Sunday 15 September.
• Dr. Suzette Delaloge co-chairs the proffered paper session on prevention policies and strategies. Additionally, she will comment on the results of the KBP-2020 study on the impact of environmental pollutants from a molecular perspective in patients with lung cancer. Sunday 15 September.
• Prof. Aurélien Marabelle co-chairs the session on basic research and translational research. He will also comment on two studies presented in this session. Monday 16 September.